SNYNF Quote, Financials, Valuation and Earnings

GSK Plc has a net margin of 36.7% compared to Sanofi's net margin of 8.44%. Sanofi's return on equity of 12.45% beat GSK Plc's return on equity of 43.01%.

Sanofi has a consensus price target of --, signalling upside risk potential of 33.5%. On the other hand GSK Plc has an analysts' consensus of $57.10 which suggests that it could fall by -1.67%. Given that Sanofi has higher upside potential than GSK Plc, analysts believe Sanofi is more attractive than GSK Plc.

Sanofi has a beta of 0.241, which suggesting that the stock is 75.938% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.477, suggesting its less volatile than the S&P 500 by 52.337%.

Sanofi has a quarterly dividend of $4.35 per share corresponding to a yield of 4.53%. GSK Plc offers a yield of 3.07% to investors and pays a quarterly dividend of $0.49 per share. Sanofi pays 88.23% of its earnings as a dividend. GSK Plc pays out 47.15% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than GSK Plc quarterly revenues of $11.5B. Sanofi's net income of $4.5B is higher than GSK Plc's net income of $966.8M. Notably, Sanofi's price-to-earnings ratio is 20.11x while GSK Plc's PE ratio is 15.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.37x versus 2.77x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 36.7% compared to Sanofi's net margin of -121.83%. Sanofi's return on equity of 12.45% beat Moderna, Inc.'s return on equity of -29.19%.

Sanofi has a consensus price target of --, signalling upside risk potential of 33.5%. On the other hand Moderna, Inc. has an analysts' consensus of $42.05 which suggests that it could fall by -18.68%. Given that Sanofi has higher upside potential than Moderna, Inc., analysts believe Sanofi is more attractive than Moderna, Inc..

Sanofi has a beta of 0.241, which suggesting that the stock is 75.938% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Sanofi has a quarterly dividend of $4.35 per share corresponding to a yield of 4.53%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 88.23% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Moderna, Inc. quarterly revenues of $678M. Sanofi's net income of $4.5B is higher than Moderna, Inc.'s net income of -$826M. Notably, Sanofi's price-to-earnings ratio is 20.11x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.37x versus 10.35x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 36.7% compared to Sanofi's net margin of -9.34%. Sanofi's return on equity of 12.45% beat Pfizer Inc.'s return on equity of 10.84%.

Sanofi has a consensus price target of --, signalling upside risk potential of 33.5%. On the other hand Pfizer Inc. has an analysts' consensus of $28.43 which suggests that it could grow by 4.89%. Given that Sanofi has higher upside potential than Pfizer Inc., analysts believe Sanofi is more attractive than Pfizer Inc..

Sanofi has a beta of 0.241, which suggesting that the stock is 75.938% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Sanofi has a quarterly dividend of $4.35 per share corresponding to a yield of 4.53%. Pfizer Inc. offers a yield of 6.35% to investors and pays a quarterly dividend of $0.43 per share. Sanofi pays 88.23% of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Sanofi quarterly revenues are $12.2B, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Sanofi's net income of $4.5B is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Sanofi's price-to-earnings ratio is 20.11x while Pfizer Inc.'s PE ratio is 20.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.37x versus 2.47x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.